A large real-world study of nearly 6,000 patients in the United Kingdom found that faricimab, a newer injectable treatment for age-related macular degeneration, can reduce the number of eye injections patients need while maintaining or improving vision. The findings suggest this bispecific antibody—which works differently than older anti-vascular endothelial growth factor (VEGF) therapies—may ease the treatment burden that has long challenged patients managing this serious eye disease. What Makes Faricimab Different From Older Eye Treatments? For decades, patients with neovascular age-related macular degeneration (nAMD), a leading cause of vision loss in older adults affecting over 200 million people worldwide, have relied on frequent eye injections to slow disease progression. Traditional anti-VEGF drugs like aflibercept and ranibizumab work by blocking a single protein that drives abnormal blood vessel growth in the retina. Faricimab takes a different approach. Faricimab is a humanized, bispecific monoclonal antibody that targets two pathways simultaneously: it blocks vascular endothelial growth factor (VEGF) like older drugs do, but it also inhibits angiopoietin-2 (Ang-2), a protein involved in inflammation and blood vessel instability. This dual mechanism addresses what researchers call the "multifactorial nature" of macular degeneration—meaning the disease involves multiple biological processes, not just one. What Did the Real-World Study Find? The FARWIDE-nAMD study, conducted across 35 National Health Service retinal clinics in the United Kingdom, tracked 5,854 patients (6,991 eyes) for 12 months after starting faricimab treatment. The research team divided patients into two groups: those who had never received anti-VEGF treatment before (26.5% of eyes) and those who switched from an older drug, primarily aflibercept (73.5% of eyes). For patients new to treatment, vision improved measurably. Their average vision score increased by 3.6 letters on the standard eye chart used in retinal research, rising from 56.4 letters at baseline to 60.1 letters after one year. For patients who switched from older drugs, vision remained stable—a meaningful outcome since maintaining vision in previously treated patients is often the realistic goal. Perhaps most importantly, faricimab required fewer injections over time. Newly treated patients received an average of 4.7 injections during the first six months and 2.2 injections during months seven through twelve. Patients who switched from older drugs received 4.5 injections in the first half-year and 3.0 injections in the second half-year. This represents a meaningful reduction in treatment frequency compared to the standard every-eight-weeks schedule of older anti-VEGF drugs. How Does This Compare to Clinical Trial Results? The real-world outcomes align closely with what researchers observed in the pivotal TENAYA and LUCERNE phase 3 clinical trials, which tested faricimab in carefully controlled settings with 671 and 658 patients respectively. Those trials showed that faricimab could extend treatment intervals to as long as every 16 weeks while maintaining vision improvements comparable to aflibercept given every eight weeks. What makes the FARWIDE study particularly valuable is that it reflects actual clinical practice rather than the controlled environment of a clinical trial. Real-world patients have diverse backgrounds, varying disease characteristics, different prior treatment histories, and different levels of treatment adherence—factors that can significantly impact outcomes. The fact that faricimab performed well in this messier, more representative population suggests its benefits are likely to hold up for most patients. What About Safety? Safety data from the study showed that serious eye complications remained rare and consistent with what was observed in the original clinical trials. The research team specifically tracked intraocular inflammation (swelling inside the eye) and presumed infectious endophthalmitis (a serious eye infection). Both complications occurred at rates comparable to the phase 3 trials, suggesting faricimab's safety profile is reliable in real-world practice. Why Does Reducing Treatment Frequency Matter? For patients with macular degeneration, the burden of frequent eye injections extends far beyond the needle itself. Patients must schedule regular clinic visits, arrange transportation, take time off work, and manage the anxiety that comes with repeated procedures. Over months and years, this accumulating burden can lead some patients to miss appointments or skip treatments, ultimately resulting in worse vision outcomes. A treatment that requires fewer injections while maintaining effectiveness could help patients stay engaged with their care. Steps to Take If You Have Age-Related Macular Degeneration - Schedule Regular Eye Exams: If you are over 50 or have risk factors for macular degeneration, see an eye specialist (ophthalmologist or optometrist) regularly to catch early signs of disease before significant vision loss occurs. - Ask Your Doctor About Treatment Options: During your appointment, discuss whether faricimab or other newer treatments might be appropriate for your specific type of macular degeneration, and ask about the expected injection frequency and potential vision outcomes. - Commit to Your Treatment Schedule: Regardless of which injection therapy you receive, maintaining consistent treatment appointments is critical to preserving vision, so work with your clinic to establish a schedule you can reliably keep. - Report Any Vision Changes Immediately: Between appointments, contact your eye doctor right away if you notice new floaters, flashes of light, or distortion in your central vision, as these may signal disease progression or complications requiring urgent attention. What's Next for Macular Degeneration Treatment? The FARWIDE-nAMD study represents one of the largest real-world evaluations of faricimab to date. While most previous real-world studies were small, single-center observations tracking fewer than 100 patients for less than six months, this research involved nearly 7,000 eyes followed for a full year across multiple clinics. The researchers note that longer-term studies evaluating durability beyond 12 months are still needed to fully understand how faricimab performs over years of treatment. The study also included a companion analysis of faricimab in diabetic macular edema (swelling in the retina caused by diabetes), another serious eye condition, though those results were reported separately. Together, these real-world evidence studies provide ophthalmologists with practical information about how faricimab performs outside the controlled setting of clinical trials, helping inform treatment decisions for the millions of patients living with vision-threatening eye diseases.
